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Abstract
Therapeutic human polyclonal antibodies (hpAbs) derived from pooled plasma from human donors are Food and
Drug Administration approved biologics used in the treatment of a variety of human diseases. Powered by the natural
diversity of immune response, hpAbs are effective in treating diseases caused by complex or quickly-evolving
antigens such as viruses. We previously showed that transchromosomic (Tc) cattle carrying a human artificial
chromosome (HAC) comprising the entire unrearranged human immunoglobulin heavy-chain (hIGH) and kappa-
chain (hIGK) germline loci (named as κHAC) are capable of producing functional hpAbs when both of the bovine
immunoglobulin mu heavy-chains, bIGHM and bIGHML1, are homozygously inactivated (double knockouts or DKO).
However, B lymphocyte development in these Tc cattle is compromised, and the overall production of hpAbs is low.
Here, we report the construction of an improved HAC, designated as cKSL-HACΔ, by incorporating all of the human
immunoglobulin germline loci into the HAC. Furthermore, for avoiding the possible human-bovine interspecies
incompatibility between the human immunoglobulin mu chain protein (hIgM) and bovine transmembrane α and β
immunoglobulins (bIgα and bIgβ) in the pre-B cell receptor (pre-BCR) complex, we partially replaced (bovinized) the
hIgM constant domain with the counterpart of bovine IgM (bIgM) that is involved in the interaction between bIgM and
bIgα/Igβ; human IgM bovinization would also improve the functionality of hIgM in supporting B cell activation and
proliferation. We also report the successful production of DKO Tc cattle carrying the cKSL-HACΔ (cKSL-HACΔ/
DKO), the dramatic improvement of B cell development in these cattle and the high level production of hpAbs (as
measured for the human IgG isotype) in the plasma. We further demonstrate that, upon immunization by tumor
immunogens, high titer tumor immunogen-specific human IgG (hIgG) can be produced from such Tc cattle.
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Introduction
Immunotherapy with human polyclonal antibodies (hpAbs) or
immunoglobulins (hIgs) prepared from the plasma of normal
and convalescing human donors have been shown to be an
effective treatment for several human diseases [1]. For
example, hpAbs derived from the plasma donated from the
general population have been widely used to treat autoimmune
and immunodeficiency diseases [2], and hpAbs from
recovering patients or pre-vaccinated individuals are effective
in treating infections caused by the same pathogens [3,4].
Human polyclonal antibodies are also used in medical
emergency crisis situations such as severe acute respiratory
syndrome (SARS) outbreaks [5]. However, the availability and
applications of hpAbs are currently limited. A paucity of
voluntary human donors has resulted in a severe shortage of
hpAbs, and donor-patient disease transmission concerns as
well as a lack of reproducibility restrict their usage [6].
To address the medical demand for hpAbs, different
alternatives have been explored to substitute or even replace
human plasma-derived hpAbs. For example, IgG or Fabs
(fragments of antigen binding), prepared from the plasma of
immunized horses or sheep has been widely used to treat
severe envenomation resulting from snake and spider bites
[7,8]. However, animal derived IgG tends to cause immune
reactions from treated patients. For example, it has been
reported that rabbit derived anti-thymocyte globulin (ATG)
causes serum sickness in patients in several clinical
applications [9,10]. Recently, an in vitro antibody production
system based on recombinant DNA and mammalian cell
culture technologies has been in the development by
Symphogen A/S [11]. This approach tries to mimic polyclonal
nature of humoral immune response by producing mixtures of
monoclonal antibodies (mAbs) that recognize multiple epitopes
of an antigen. Such an approach, if successful, has the
potential to produce antibody mixtures in large quantities within
a well defined system, allowing for improved reproducibility and
elimination of the risks associated with human plasma-derived
hpAbs. However, these antibody mixtures do not fully take
advantage of the vastness of antibody diversity generated by
natural immune responses. Additionally, as pre-defined
antigens are needed to identify the mAbs and a lengthy
process is needed to engineer cell lines expressing the
recombinant mAbs, this system may not be useful for treatment
of diseases in which antigens are not well characterized, such
as in autoimmunity, nor in dealing with sudden outbreaks of
infectious diseases such as the 2002 SARS epidemic [5].
To harness the power of natural humoral immune response
not only for its unparalleled diversity but also for its capability to
respond rapidly after antigen exposure, we have been
developing a transchromosomic (Tc) bovine system that
quickly produces diverse hpAbs in large quantities [12].
Previously, we reported the generation of Tc cattle carrying a
human artificial chromosome (HAC) comprising the entire
unrearranged germline loci of human immunoglobulin heavy-
chain (hIGH) and kappa light-chain (hIGK) with homozygous
double knockouts (DKO) of the two bovine Ig mu heavy-chain
loci (bIGHM-/- and bIGHML1-/-) [12]. In these cattle, the
production of serum hpAbs, as measured for its hIgG isotype,
was only up to 1.5 g/l which is significantly lower than the
physiological serum IgG levels of approximately 5-10 g/l in
normal humans. The level of fully hIgG (hIgG kappa; hIgG/
hIgκ) was even lower, at only approximately 0.65 g/l [12].
Further analysis of the Tc cattle showed suboptimal
development of B cells, indicating that the low hIgG production
in these Tc cattle is the result of poor B cell development [12].
The pre-B cell receptor (pre-BCR), comprising of IgM and
invariant surrogate light-chains VpreB and lambda5 (λ5), plays
critical roles for pre-B cell proliferation and maturation during B
lymphogenesis [13]. It transmits B cell proliferation and
maturation signals to the nucleus through its interaction with
the B cell transmembrane proteins α and β immunoglobulins
(Igα and Igβ) [14-16]. We reasoned that the poor B cell
development and low hIgG production in the previously
produced Tc cattle could be due to a compromised function of
pre-BCR, as in the HAC/DKO cattle the bIgM in the pre-BCR
complex is replaced by hIgM. Specifically, we speculated that,
due to the difference in protein sequences between human and
bovine IgMs, hIgM may not interact with bovine surrogate light-
chains effectively; similarly, the functional interaction between
the CH-TM domains of hIgM with the bovine Igα and Igβ
proteins for transmitting the cellular signals from a pre-BCR to
the nucleus may also be compromised. Therefore, in an effort
to improve B cell development and hIgG production in Tc
cattle, we sought to enhance pre-BCR function by engineering
a new HAC into which, in addition to the hIGH, hIGK and hIGL
chromosome loci that carry the entire human immunoglobulin
gene repertoire, the human VpreB (hVPREB1) and λ5 (hIGLL1)
genomic loci from human chromosome 22 (hChr22) was
incorporated, and part of CH and TM domains, CH2-TM, of
hIGHM gene, was replaced by the corresponding bovine gene
sequence (bovinization of the CH2-TM domains of hIGHM). As
IgM interacts with surrogate light-chains and Igα/Igβ via its
variable (V) and CH-TM domain, respectively, such
modifications would restore the natural intra-species protein-
protein interactions in the pre-BCR (Figure 1). We also
envisioned that the bovinized CH-TM domain would also
improve the functionality of hIgM in interacting with bovine B
cell proteins that are involved in B cell activation and
proliferation. Our results showed that DKO Tc cattle carrying
the modified HAC have greatly improved B cell development
and produced up to 9 g/l of hIgG in the plasma. Through
immunization studies, we further demonstrated that these Tc
cattle are responsive to immunization with the tested tumor
antigens and produce high titer tumor-specific hIgG.
Results
Modification hChr14 for HAC Construction
1. hChr14 modification.  For deleting the non-
immunoglobulin genes on hChr14, intact hChr14 was
transferred to chicken DT40 cells by using Micro-cell Mediated
Chromosome Transfer (MMCT) for chromosomal modification
as described previously [17]. We employed a Cre/LoxP
mediated site-specific recombination strategy to delete the
DNA sequences on hChr14 that are irrelevant to
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immunoglobulin locus. Specifically, we integrated two lox511
sequences into hChr14, one at the AL512355 locus (about 300
kb centromeric to the hIGH locus) and the other at AL391156
locus (about the 85 Mb centromeric to the AL512355 locus),
through homologous recombination for deleting the 85 Mb
sequences on hChr14 between these two loci (Figure 2A). In
order to facilitate the identification of the correctly deleted DT40
cell clones, we also integrated a CAG promoter and a hisD
selection cassette along with the lox511 sequence at locus
AL512355 and the promoter-less puromycin (puro) gene along
with the second lox511 sequence and a hygromycin selection
cassette at locus AL391156, respectively (Figure 2A; for the
details, see Materials and Methods). Such strategy ensured
that only the correctly deleted hChr14 acquired puromycin
resistance and was sensitive to hygromycin and histidinol
(hisD) (Figure 2A). Post electroporation of the DT40 cells with a
Cre-expressing vector; the correctly deleted colonies were
screened by genomic PCR and confirmed by fluorescence in
situ hybridization (FISH) (data not shown). To prepare the
correctly shortened hChr14 (labeled D) as one of the building
blocks for the construction of the cKSL-HACΔ, it was further
modified by integrating a loxP sequence and a GFP reporter
cassette at the RNR2 locus as described in Materials and
Methods and previously [12]. Through extensive genomic PCR
analysis (data not shown) and FISH (Figure 2B), a DT40 clone,
14D, was confirmed to have the loxP integration at the desired
locus and selected for the bovinization of the CH2-TM2 domain
of hIgM (see below).
2. Bovinization of hIgM CH2-TM Domain.  In order to
improve the functional interactions between the hIgM and bIgα/
Igβ proteins in the pre-BCR, as well as the overall functionality
of hIgM in Tc bovine B cells, we constructed a gene-targeting
vector to bovinize the CH2-TM2 domain of hIgM that is
involved in interacting with bIgα/Igβ [18]. The bovine genomic
DNA used for the gene targeting vector construction were
cloned from an isogenic bovine genomic phage library (see
Materials and Methods). We employed a positive and negative
selection for this gene targeting event: a zeocin (Zeo)
expression cassette flanked by loxP sequences (floxed-Zeo; for
eventually removing of the Zeo cassette from the bovine
genome) was inserted into the intron between CH 4 and TM1
for positive selection and a dT-A selection cassette was added
outside of the 3’-homologous arm for negative selection (Figure
3). A DT40 cell clone, CH2D4, was confirmed by extensive
genomic PCR genotyping experiments (data not shown) to
carry the correctly targeted 14D and was selected for the final
HAC construction.
Modification of hChr22 for HAC Construction
To isolate the human chromosome fragment that contains
the entire hIGL gene cluster and the hSLC locus (hVPREB1/
hIGLL1), we set out to modify hChr22 as outlined in Figure 4.
Specifically, a DT40 cell line, 52-18, carrying the intact hChr22
was first truncated at the AP000350 locus with the targeting
vector pTELCAGzeoSLFR and then was further modified with
the targeting vector p553CAGlox2272bsrDT to integrate the
lox2272 and the CAG promoter at the locus AP000553.
Through extensive genomic PCR screening, a DT40 clone,
STL54, was identified to carry the correctly modified hChr22
(Figure 4).
Modification of hChr2 for HAC Construction
We previously engineered a hChr2 fragment containing the
entire hIGK locus in DT40 cells [12]. We further modified this
hChr2 fragment carried by a DT40 clone (named as κTL1) with
the targeting vector pTEL’hisDpurolox2272F9R9 to both truncate
the hChr2 fragment and integrate the lox2272 and the
promoter-less puro gene at the AC104134 locus (Figure 5).
Locus AC104134 is about 300 kb telomeric to the hIGK
constant region Cκ gene, IGKC, and this truncation event
deleted all the non-immunoglobulin chromosomal sequences
between this locus and the telomere of the p-arm on hChr2.
Figure 1.  Diagrams of pre-BCRs in κHAC/DKO and cKSL-HACΔ/DKO cattle.  Protein molecules/domains encoded by human
genes are drawn in red while bovine in blue. The dotted double-lines represent B cell membrane.
doi: 10.1371/journal.pone.0078119.g001
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Figure 2.  Modification of hChr14.  (A) A lox511 sequence along with the promoter-less puro cassette was integrated at the
AL512355 locus with gene targeting vector p14CEN(FR)hygpurolox511DT, and a lox511 sequence along with a CAG promoter and a
hygromycin (hyg) selection cassette was integrated at locus AL512355 with gene targeting vector pSC355CAGlox511hisDDT.
Following Cre expression, the ~85 Mb genomic sequence was removed rendering puro expression. A loxP sequence and a GFP
reporter cassette was then integrated at the RNR2 locus to generate 14D. (B) FISH analysis of a DT40 clone, 14D, containing the
correctly modified hChr14.
doi: 10.1371/journal.pone.0078119.g002
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DT40 colonies were screened with genomic PCR (data not
shown) for the correctly modified hChr2, and clone K53 was
identified and selected for the final HAC construction (Figure
5).
Translocation between hChr22 and hChr2:
Construction of SLK HAC Carrying the hSLC, hIGL and
hIGK Loci
With the chromosome cloning system we described
previously [12], we translocated the hSLC and hIGL loci on
hChr22 to the AC104134 locus adjacent to hIGK locus on
hChr2 through Cre/loxP mediated site-specific chromosome
recombination (Figure 6). Specifically, a DT40 clone K53
carrying the hChr2 fragment with the previously inserted hisD-
lox2272-promoter less puro and hyg-loxP cassettes, and a
DT40 clone STL54 carrying the hChr22 fragment with the
previously inserted bsr cassette and lox2272, were fused via
whole cell fusion (WCF) to generate DT40 hybrid cells.
Colonies derived from WCF were screened for the presence of
both hChr2 and hChr22 with genomic PCR and FISH by using
human COT-1 DNA as the probe as described in Materials and
Methods. Clone SLK2 was identified as a positive clone (Figure
7). Finally, to translocate the hSLC and hIGL loci on hChr22 to
the hIGK locus at AC104134 on hChr2 through site-specific
recombination, SLK2 was transfected with the Cre expression
plasmid to induce the recombination between the two lox2272
sites that were previously inserted at the AC104134 locus on
the hChr2 and AP000553 locus on the hChr22, respectively
(Figure 6). Puromycin resistant colonies (conferred by
Figure 3.  Bovinization of hIgM CH2-TM Domain.  The upper line shows the genomic configuration of the CH 1-TM2 domain
of hIgM, the middle line shows the gene targeting vector pCH2CAGzeoDT, and the bottom line depicts the modified CH2-
TM2 domain of hIgM in a DT40 cell clone, CH2D4.
doi: 10.1371/journal.pone.0078119.g003
Figure 4.  Modification of hChr22. The intact hChr22 carried in a DT40 cell line, 52-18, was first truncated at the AP000350
locus with the targeting vector pTELCAGzeoSLFR. A DT40 clone, ST13, carried the truncated hChr22 was transfected with
targeting vector p553CAGlox2272bsrDT to integrate the lox2272 and the CAG promoter at the locus AP000553. The distance
between AP000350 and AP000553, where the hIgL and hSLC are located, is about 2 Mb.  
doi: 10.1371/journal.pone.0078119.g004
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reconstitution of the CAG promoter-lox2272-puro cassette at
the translocation site) were screened by genomic PCR with
CAGpuro-F3R3 primers, followed by direct sequencing of the
PCR product. Clone SLKH6 was identified to contain the
correctly generated SLK HAC (Figure 6). We subsequently
transferred the SLK HAC from SLKH6 to plain DT40 cells by
MMCT. Puromycin resistant and blasticidin S sensitive colonies
were screened by extensive genomic PCR (data now shown);
candidate clones were further confirmed by two-color FISH
using the hChr2 painting probe labeled with Rhodamine and
the hChr22 painting probe labeled with Fluorescein (Figure 7).
We chose clone SLKD18 for subsequent HAC engineering.
Construction of cKSL-HACΔ
The cKSL-HACΔ was constructed in chicken DT40 cells as
outlined in Figure 8. DT40 clones, CH2D4 containing the CH2D
HAC and SLKD18 containing the SLK HAC established above
were fused by WCF to generate DT40 hybrid clone cKSLD22.
After confirming with genomic PCR (data not shown) and FISH
with human COT-1 DNA as the probe (Figure 8), the selected
clone cKSLDH22 was induced for site-specific translocation
between the two loxP sites at the cos138 locus on the SLK
HAC and another at the RNR2 locus on the CH2D HAC by Cre
expression. Cre expression also resulted in the deletion of the
floxed CAG promoter-zeo cassette within the cIgM (CH2)
domain. Recombinants were enriched by sorting of GFP
positive DT40 cells, as GFP expression was conferred by
reconstitution of the PGK promoter-loxP-GFP cassette at the
translocation site (data not shown). cKSLDH22 was finally
identified as a DT40 hybrid cell line retaining the cKSL-HACΔ
and subjected to extensive genomic PCR (data not shown) and
three-color FISH by DNA probes recognizing the hIGH, hIGK
and hIGL loci, respectively, for structural confirmation.
The constructed cKSL-HACΔ was transferred to Chinese
hamster ovary (CHO) cells by MMCT to establish CHO-based
master cell banks. The structural integrity of the constructed
Figure 5.  Modification of hChr2.  A previously engineered hChr2 fragment containing the entire hIGK locus in a DT40
clone, κTL1 [12], was further modified with gene targeting vector pTEL’hisDpurolox2272F9R9 to both truncate the hChr2
fragment and integrate the lox2272 and the promoter-less puro gene at the AC104134 locus. The DT40 clone carrying the
truncated form of hChr2 was named as K53. The upper panel of the figure shows the structures of hChr2 before and after
truncation. The lower panel of the figure depicts the homologous recombination event mediated by the
pTEL’hisDpurolox2272F9R9 gene targeting vector.
doi: 10.1371/journal.pone.0078119.g005
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cKSL-HACΔ was further examined by extensive genomic PCR,
array comparative genomic hybridization and three-color FISH
(data not shown). To our knowledge, this is the first report of
construction of an artificial chromosome composed of
structurally defined human chromosome fragments from three
different chromosomes.
Establishing cKSL-HACΔ/DKO Bovine Fibroblast Cell
Lines and Tc Cattle Cloning
To clone cKSL-HACΔ/DKO cattle, we established cKSL-
HACΔ/DKO bovine fibroblast donor cells by transferring the
newly constructed cKSL-HACΔ from CHO cells into the DKO
(bIGHM-/- and bIGHML1-/-) bovine fibroblast cells via MMCT.
Cells from the fibroblast colonies derived from MMCT were
used as donors for somatic cell chromatin transfer (CT) as
previously described [19]. Cloned embryos developed to the
blastocyst stage were singly transferred into recipient cows
(one cloned blastocyst to one recipient cow) either for
establishing gestation day 40 fetal cell lines or directly for Tc
cattle production. Some of the established cell lines were also
used for cKSL-HACΔ/DKO cattle cloning. In total, 314 embryo
transfers were conducted, with 114 from cell colonies (Col) and
200 from fetal cell lines, and 17 healthy calves were produced
(Table 1).
We confirmed the cKSL-HACΔ/DKO genotype of these Tc
calves with extensive genomic PCR with primers amplifying all
of the junction points created during the cKSL-HACΔ
construction process (Figure 9A and B). Such analyses were
performed on the genomic DNAs isolated both from peripheral
blood lymphocytes samples and ear biopsies collected from Tc
calves (Figure 9B shows a representative gel image of PCR
products amplified from the genomic DNAs isolated from
peripheral blood lymphocytes). The retention of cKSL-HACΔ
and its structural integrity in the produced Tc calves were
Figure 6.  Translocation between hChr22 and hChr2. A DT40 clone (K53) carrying the previously modified hChr2
fragment is fused with a DT40 clone (STL54) carrying the previously modified hChr22 fragment via WCF to generate DT40
hybrid clone SLK2. Transfection of SLK2 by Cre-expression plasmid induces the recombination between the two lox2272
sites, one at the AC104134 locus on the hChr2 and another at AP000553 locus on the hChr22. The translocated
chromosome (carried by DT40 clone SLKH6) was transferred to plain DT40 cells by MMCT to generate clone SLKD18. The
lower panel of the figure depicts the Cre/loxP mediated DNA recombination event. Note that only the correctly DNA
recombination event activates the puro gene.  
doi: 10.1371/journal.pone.0078119.g006
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examined both in the peripheral blood lymphocytes and
fibroblasts established from ear biopsies of newborn calves
with FISH. The retention rate of cKSL-HACΔ in three of the
analyzed calves is shown in Figure 9c.
B Cell Development and Human IgG Production Profile
in cKSL-HACΔ/DKO Tc Cattle
In order to investigate the impact of HAC modification on B
cell development in Tc cattle, we analyzed the peripheral blood
mononuclear cells (PBMCs) in newborn animals with flow
cytometry. We used anti-hIgM antibody to detect IgM+ B cells in
cKSL-HACΔ/DKO animals, as the anti-hIgM antibody can still
recognize the retained CH 1 domain of the bovinized hIgM. In
comparison to the κHAC/DKO animals [12], cKSL-HACΔ/DKO
calves demonstrated higher percentage IgM-single positive
(IgM+) and IgM/CD21-double positive (IgM+/CD21+) B cells
(Figure 10).
We measured the serum concentrations of total hIgG, i.e. all
the hIgG regardless of whether it pairs with human lambda or
kappa (hIgG/hIgλ/κ) light-chains or bovine lambda or kappa
(hIgG/bIgλ/κ) light-chains, as well as fully hIgG (hIgG/hIgλ/κ
only), when the Tc calves reached to 5-6 months of age. Even
though the total hIgG levels varied among these Tc calves, the
overall total hIgG production was found to be dramatically
improved compared to the κHAC/DKO Tc animals, at levels
comparable to the physiological hIgG levels found in healthy
humans (Figure 11A). Nevertheless, the average level of fully
hIgG (hIgG/hIgλ/κ) produced by cKSL-HACΔ/DKO calves was
about 0.383 g/l which is only about 8.5% of the total hIgG. This
is not unexpected, as the bovine immunoglobulin light-chain
genes, lambda and kappa, were not genetically knocked out in
such Tc cattle, the expression of human light-chain loci on the
HAC would be easily overwhelmed by the endogenous bovine
light-chain locus resulting in the produced hIgG mostly to be
chimeric (hIgG/bIgk/l). We also analyzed the IgG subclass
distribution in the plasma of such Tc animals and showed that
IgG1 is the dominant subclass (hIgG1/hIgG2 ratio >1) which is
similar to what is observed in the plasma of healthy humans
(Figure 11B). Therefore, we produced Tc cattle expressing
physiological levels of hIgG with a subclass distribution profile
similar to that of healthy humans.
Figure 7.  FISH analysis of DT40 clones carrying the corrected modified human chromosomes.  For the hybrid DT40 clone
SLK2, the presence of both hChr2 and hChr22 was detected by human COT-1 DNA as the probe; for DT40 clones carrying the
translocated human chromosomes, a two-color FISH assays were conducted: the hChr2 painting probe was labeled with
Rhodamine and the hChr22 painting probe was labeled with Fluorescein.
doi: 10.1371/journal.pone.0078119.g007
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cKSL-HACΔ/DKO Tc Cattle Produce High Titer hIgG
against Tumor Antigens
As our ultimate goal is to produce high titer antigen-specific
hpAbs from the Tc cattle, we conducted an immunization study
by immunizing two Tc cattle with a human oral squamous cell
carcinoma cell line as an antigen. To evaluate antibody titers
specific to the tumor cells, we collected sera from each of the
immunized Tc cattle at 14 days post second vaccination (V2)
and performed flow cytometry-based immunofluorescence
assay. As shown in Figure 11c, Tc calves readily responded to
immunization and generated high hIgG titer against human oral
squamous cell carcinomas post V2 as demonstrated by the
mean fluorescence intensity (MFI) of tumor cells stained with
the sera from immunized cattle. Furthermore, when MFI was
measured by using anti-human kappa antibodies (to detect fully
hIgG staining of the tumor cells, see Materials and Methods),
measurable MFI was detected even after a 10,000-fold dilution
of the sera. However, the titer against human tumor cells from
fully hIgG is significantly lower than that from total hIgG. This
was expected due to the fact that bovine immunoglobulin light-
Table 1. Pregnancy and live calf data from cell lines used to
produce cKSL-HAC/DKO Tc cattle.
Cell line ID Recipients implanted Pregnant at (%) Live calves (%)
  40 d 120 d Term  
Y692 (Col) 74 28 (38) 14 (23) 8 (13) 7 (11)
L289-2 55 12 (22) 9 (16) 4 (7) 2 (4)
598R 85 25 (29) 12 (14) 3 (4) 2 (2)
Y692 (Col) 40 5 (13) -   
L383 60 33 (55) 23 (38) 8 (13) 6 (10)
doi: 10.1371/journal.pone.0078119.t001
Figure 8.  Construction of cKSL-HACΔ.  DT40 clones carrying modified hChr14 (CH2D4) and modified hChr2/hChr22 (SLKD18),
respectively, were fused by WCF to generate DT40 hybrid clone cKSLD22. The presence of the two modified human chromosomes
in cKSLDH22 clone was confirmed by FISH with human COT-1 DNA as the probe. Transfection of cKSLDH22 clone with Cre-
expression plasmid induced for site-specific translocation between the two loxP sites at the cos138 locus on the SLK HAC and
another at the RNR2 locus on the CH2D HAC. The presence of the three human immunoglobulin loci, hIgH, hIgK and hIgL, as a
single HAC was confirmed by three-color FISH, with the DNA probes for hIgH, hIgK and hIgL labeled with SpectrumRed,
SpectrumGreen, and SpectrumOrange, respectively.
doi: 10.1371/journal.pone.0078119.g008
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Figure 9.  Establish DT40 clones carrying the engineered cKSL-HACΔ.  (A), Diagram of cKSL-HACΔ and the locations of PCR
primers used to examine cKSL-HACΔ structural integrity. (B), A representative gel image of PCR products for some of the junction
points in the cKSL-HACΔ from genomic DNA isolated from PBL of Tc claves 1921, 1922 and 1923. (C) cKSL-HACΔ retention rates
in Tc calves 1921, 1922 and 1923 analyzed by FISH. PBL: peripheral blood lymphocytes; FB: fibroblasts.
doi: 10.1371/journal.pone.0078119.g009
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chain genes have not been genetically inactivated in these Tc
cattle and only roughly 8% fully hIgG is produced.
Discussion
There are numerous technical challenges in producing fully
hpAbs totally independent of the human immune system. First,
as the human immunoglobulin genes and gene segments exist
as gene clusters spanning large regions on three
chromosomes, the only feasible way currently of delivering
such a large size of human genomic DNA into a biological
system for hpAbs production is through the engineering of
HACs that comprise all or most of the human Ig genes. We
report here the successful engineering of a HAC comprising
the entire hIg gene repertoire that reside on three different
human chromosomes, i.e. the IgH locus from hChr14, the Igk
locus from hChr2, and the Igλ and surrogate light-chain loci
from hChr22. The second challenge for fully hpAbs production
by a recombinant system is to have a biological mechanism to
efficiently tap into the genetic information provided by the
immunoglobulin gene repertoires for generating the seemingly
unlimited diversity of hpAbs. The mammalian humoral immune
system is currently the only conceivable biological system that
has such functionality. Therefore, we set out to develop a Tc
animal system for fully hpAbs production. We chose bovine for
the large body size, which makes it feasible to collect large
volumes of plasma, a prerequisite for producing large amounts
of therapeutic hpAbs.
However, our initial success in producing antigen-specific
fully hpAbs in the Tc cattle system was limited by the relatively
low levels of total hpAbs production and the low level of fully
Figure 10.  Flow cytometry analysis of B cell
development in cKSL-HACΔ/DKO Tc cattle. The
percentages of IgM-single positive (IgM+) and IgM/CD21-
double positive (IgM+/CD21+) B cells in PBMCs from
newborn animals were compared between κHAC/DKO and
cKSL-HACΔ/DKO calves.  
doi: 10.1371/journal.pone.0078119.g010
hpAbs production [12]. In this report, we addressed this issue
by improving the pre-BCR function through incorporating the
human surrogate light-chain genomic locus into the HAC and
by bovinizing the HAC in the hIgM domain that is involved in
interacting with bovine Igα and Igβ signal molecules in the pre-
BCR complex. Our results showed that restoring intra-species
interactions between proteins in pre-BCR had a positive impact
on Tc bovine B cell development as demonstrated by the
increased development of IgM+/CD21+ B cells in newborn Tc
calves (Figure 10). Very importantly, a dramatic improvement
in total hIgG production was shown in these Tc calves as
compared to our previously reported κHAC/DKO Tc animals,
likely due to improved B cell development. Finally, we
demonstrated that Tc cattle developed here are responsive to
antigen immunization and generate high titer antigen-specific
human polyclonal antibodies (Figure 11). Therefore, we
developed an improved Tc bovine system to produce large
quantities of hpAbs.
There are apparently some limitations that still exist in this Tc
bovine system, as the endogenous bovine immunoglobulin
light-chain genes are intact and 80% of total serum hIgG
produced is chimeric composing the hIgG heavy and bIg light-
chains. While such chimeric hIgG are fully functional in
recognizing antigens (our unpublished data) and are likely
much less immunogenic than fully animal derived antibodies for
therapeutic applications, it is obvious that fully human
antibodies are more desirable as a biotherapeutic. This is
especially true for long-term, repetitive treatments. Therefore,
we have recently knocked out the bovine lambda light genes by
deleting the entire bovine lambda light-chain gene cluster
(manuscript in preparation) and are in the process of knocking
out the bovine kappa light-chain genes. Accompanying our
efforts to genetically improve our Tc bovine system, we also
have developed robust immunization protocols in Tc bovine for
producing high titer immunogen-specific fully hpAbs. The fact
that high titer antigen-specific hpAbs can be produced from Tc
animals through hyper-immunization will offer great advantages
over the human plasma derived hpAbs in that the titers to
certain pathogens from human plasma derived hpAbs tends to
be low and sources of convalescent plasma are often difficult to
obtain.
In summary, our improved Tc bovine system for the
production of fully hpAbs has further advanced achieving the
goal of producing large quantities of therapeutic hpAbs as an
alternative for plasma derived hpAbs.
Materials and Methods
Ethics statement
The animal protocols contained in the study were approved
by the Hematech (previous name of Sanford Applied
Biosciences) Institutional Animal Care and Use Committee
(IACUC) (USDA Research Facility 46-R-0008, OLAW
#A4438-01, AAALAC #001114). Care of all vertebrate animals
is subject to regular review by the IACUC and complies with
Animal Welfare laws and regulations of the United States.
Periodic health evaluations (blood profile, weight, etc.) are
made by Veterinary Service to ensure that Tc cattle are
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Figure 11.  Human IgG production profile in cKSL-HACΔ/DKO Tc cattle. (A) Comparison of average total hIgG (left panel)
and fully hIgG (hIgG/hIgκ) concentrations in the sera of κHAC/DKO and cKSL-HACΔ/DKO calves at 5-6 months of age. (B)
IgG subclass distribution in the plasma of cKSL-HACΔ/DKO calves. (C) Mean fluorescence intensity (MFI) of tumor cells
stained with the sera from immunized cattle. Left panel shows the MFI with anti-hIgG antibodies (measuring total hIgG);
right panel shows the MFI with anti-hIgκ antibodies (measuring fully hIgG/hIgκ).  
doi: 10.1371/journal.pone.0078119.g011
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healthy. All Tc bovine receive adequate housing, feed, access
to water and bedding. Daily observations are made by
herdsmen to ensure that appropriate standards of animal care
are being met. Sanford Applied Biosciences uses the Guide for
the Care and Use of Laboratory Animals and the Guide for the
Care and Use of Agricultural Animals Used in Agricultural and
Research Teaching for animal care standards. Animal care and
use and facilities are inspected by the IACUC on a semiannual
basis. Animals may have to be euthanized due to unfortunate
events like terminal illness and trauma. Methods of euthanasia
must follow the guidelines given by the American Veterinary
Medical Association (AVMA) 2013. These are acceptable
methods by the AVMA and they have been approved by the
IACUC. All protocols and procedures used in the Animal Care
and Use Program that may cause discomfort, distress and
pain, and injury are reviewed by the IACUC for appropriate
management practices. Analgesic, anesthetics and
tranquillizing drugs are used when appropriate under
supervision of Veterinary Services. Veterinarians and
herdsmen use cattle chute for restraining when needed. Cattle
are not restrained for more than four hours per day.
Genomic library
Genomic DNA isolated from primary bovine fibroblast cell
lines established from Holstein dairy cattle was used to
construct the bovine genomic library. Each λ phage-based
genomic library was constructed using λFIX II vector through a
custom library construction service (Lofstrand Labs Ltd.,
Gaithersburg, MD). Library screening and λ phage DNA
extraction/purification was done as described previously [12].
Construction of gene targeting vectors
pTEL’hisDpurolox2272F9R9: A previously described plasmid
pTELpuro [12] was modified by replacing the puro gene with
the hisD gene, Eco RI site with Srf I, and Spe I site with Pme I
site to generate plasmid pTEL'hisDPm. A pPURlox2272
plasmid was constructed by cloning the double strand lox2272-
containing oligo DNA (Oligo DNA pair 1) into HindIII site of
plasmid pPUR (BD Bioscience Clontech, Mountain View, CA).
In parallel, a 7.3kb homologous arm (amplified by using a PCR
primer pair, kD-F9 and kD-R9, in 40 cycles of 98 °C for 10 s
and 68 °C for 9 min) was subcloned into Bam HI site of plasmid
pTEL’hisDpurolox2272. Then the Bam HI fragment from the
pPURlox2272 was blunted and cloned to Pme I site of the
pTEL'hisDPm to generate the pTEL’hisDpurolox2272F9R9
vector.
pTELCAGzeoSLF2R2: plasmid pTELpuro was modified by
converting the Eco RI site to Pme I and by replacing the puro
gene with CAGzeo gene to generate vector
pTELCAGzeo(Sr)Pm. Then the second homologous arm
(7.4kb) (amplified by using a PCR primer pair, SL-F2 and SL-
R2, in 40 cycles of 98 °C for 10 s and 68 °C for 9 min) was
cloned into Bam HI site of the plasmid pTELCAGzeo(Sr)Pm to
generate pTELCAGzeoSLF2R2.
p553CAGlox2272BsrDT: A previously described targeting
vector pHCF2loxPHyg [17] was modified by replacing the
homology arm sequence of the HCF2 gene with that of the
AP000553 (amplified by using a PCR primer pair, 553-F3 and
553-R3, in 40 cycles of 98 °C for 10 s and 68 °C for 15 min) to
generate p553loxPHyg(F). This plasmid was Not I-digested
and self-ligated to remove loxPHyg cassette, followed by
cloning of dT-A fragment into Srf I site. In parallel, pDRIVE-
CAG (InvivoGen, San Diego, CA) was modified by replacing
the lacZ fragment (Bsr GI-Eco RI) with the loxP-containing
oligo DNAs (Oligo DNA pair 2). Then Sda I-Swa I fragment was
liberated from this plasmid and cloned into Pst I/Sma I-digested
pBluescript SK− (Stratagene, La Jolla, CA) to generate
pCAGloxP. The loxP sequence was then replaced by the
lox2272-containing sequence that was generated after
annealing Oligo DNA pair 3. Then the bsr gene was added to
Spe I site to generate pCAGloxP2272bsr. Finally, the Not I-Kpn
I fragment (CAG-lox2272-polyA-bsr) was cloned into Not I site
to complete p553CAGlox2272BsrDT.
pSC355CAGlox511hisDDT: a genomic DNA fragment (10.2
kb) as one of the homologous arms was amplified by using a
PCR primer pair, SC355-F3 and SC355-R3, in 40 cycles of 98
°C for 10 s and 68 °C for 15 min. This PCR product was cloned
into Spe I site of a plasmid pBluescript where the Kpn I site
was converted to Srf I site to generate pSC355F3R3. The
pCAGloxP plasmid was similarly modified by replacing the loxP
sequence with the lox511-containing sequence (Oligo DNA pair
4) and by adding the hisD gene to Spe I site to generate
pCAGlox511hisD. The Not I-Kpn I fragment (CAG-lox511-
polyA-hisD) from pCAGlox511hisD was cloned into the Eco RV
site of pSC355F3R3. Finally, the dT-A cassette was cloned into
Not I site to complete pSC355CAGlox511hisDDT.
p14CEN(FR)hygpurolox511DT: a genomic DNA fragment
(10.2 kb) for another homologous arm was amplified by using a
PCR primer pair, 14CEN-F and 14CEN-R, in 40 cycles of 98 °C
for 10 s and 68 °C for 15 min. This PCR product was cloned
into Bam HI site of a plasmid pBluescript where the Kpn I site
was converted to Pme I site to generate p14CEN(FR). The
modified lox511-containing oligoDNA (Oligo DNA pair 5) was
cloned into Hin dIII site of a plasmid pPUR (BD Bioscience
Clontech, Mountain view, CA) to generate plasmid
pPURlox511. The Bam HI fragment from the pPURlox511 was
cloned to Bam HI site of pBluescript SK− (Stratagene, La Jolla,
CA), followed by cloning of the hyg gene to Eco RV, to
generate pHygPurolox511. The Not I-Kpn I fragment (puro-
lox511-hyg) was cloned into the Hpa I site of p14CEN(FR).
Finally, the dT-A cassette was subcloned into Pme I to
complete p14CEN(FR)hygpurolox511DT.
pRNR2loxPbsrDT: the previous vector pRNR2loxPbsr [17]
was modified to construct the pRNR2loxPbsrDT by simply
adding the dT-A cassette.
pCH1CAGzeo(R)DT(F): a genomic λ phage library was
constructed from CHO cells containing the κHAC using λFIX II
vector through a custom library construction service (Lofstrand
Labs Ltd., Gaithersburg, MD). The genomic library was
screened for hIGHM constant region by using a probe that was
a PCR product (with PCR primer pair, hCμ-FR). A 1.7 kb of
Pml I fragment from one of the positive phage clones was
cloned into Sma I site of pBluescript to generate pCH1S (F).
Then a 1 kb of Sac I-Pml I bovine IGHM genomic fragment
from plasmid pBCμAY37-95 (a clone containing IGHM bovine
genomic fragment derived from lambda phage based genomic
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library [12] was subcloned into Pst I site of the pCH1S (F) to
generate pCH1SSP (F). A 7.4 kb of the Sma I-Eco RI fragment
from another positive phage clone was cloned into Eco RV/Eco
RI-digested pCH1SSP (F) to generate pCH1SL. In parallel, a
3.5 kb of Sac I fragment from pBCμAY37-95was cloned into
pBluescript and then the Xho I fragment of floxed CAGzeo was
cloned into Van91 I site to generate pmAYSazeo (F). The Sac I
fragment from the pmAYSazeo (F) was then cloned into
blunted Eco RI site of pCH1SL resulting in pCH1zeo (F). As a
final step, the dT-A cassette was cloned into Not I site of the
pCH1zeo (F) to complete pCH1CAGzeo(R)DT(F).
pCH2CAGzeoDT: an annealed oligo DNA pair, SeSp, which
contains human and bovine junction region at CH2 flanked by
SexAI and Sph I site, was cloned into blunted Pst I site of
pBluescript. From the pBCμAY37-95, a 2 kb of Sph I-Bam HI
fragment was cloned into Sph I-Bam HI site of the plasmid
generated by cloning SeSp into the Pst I site, generating
pmAYSpB. Similarly, a 2 kb of Bam HI-Pml I fragment from the
pBCμAY37-95 was cloned into Bam HI-Pme I site (converting
the original Spe I site) resulting in pmAYSpBPml. A 0.6 kb of
Eco RI-Sex AI fragment from the above phage clone was
cloned into Eco RI-Sex AI site of the pmAYSpBPml to generate
pRISe. Then the floxed CAGzeo was cloned into Van91 I site
of the pRISe to generate pRISeCAGzeo (R), of which Not I site
was converted to Eco RI site, generating pRISeCAGzeoE.
Meanwhile, 1.7 kb of Pml I fragment from the above clone 4
was subcloned into Sma I site of pBluescript of which Eco RV
site was converted to Mlu I site, generating pCH2S (F). 6.6 kb
of Mlu I-Eco RI fragment from the above clone 1 was cloned
into Mlu I-Eco RI of the pCH2S (F), generating pCH2LS. Then,
the Eco RI fragment from the pRISeCAGzeoE was subcloned
into Eco RI site of the pCH2LS, generating pCH2CAGzeo (F).
As a final step, the dT-A cassette was subcloned into Not I site
of the pCH2CAGzeo (F) to complete the pCH2CAGzeoDT.
Transfection of chicken DT40 cells for HAC vector
construction
HAC vector construction was carried out as previously
described [12,17,20]. Briefly, DT40 (Japan Collection of
Research Bioresources, #9130, Japan) cells containing each
hChr fragment were electroporated by using Gene Pulser II
(550 V, 25 μF) with ~25 μg of each targeting vector. DT40 cell
colonies were selected by the appropriate drugs based the
experimental design. The concentrations of drugs used are the
following: G418 (2 mg/ml), puromycin (0.5 μg/ml), hygromycin
B (1.5 mg/ml), blasticidin S (15 μg/ml), histidinol (0.5 mg/ml) or
zeocin (1 mg/ml). Genomic DNAs isolated from selected cell
colonies were subjected to PCR screening to identify the
colonies with the correct gene targeting events.
Micro-cell Mediated Chromosome Transfer
MMCT was done with each HAC vector as described
previously [12,17,20].
Genomic PCR and RT-PCR
These analyses were implemented as previously described
[12,17,20,21]. The PCR primer sequences used are listed in
Table S1 (Oligo DNA information). All the PCR products were
resolved on 0.8 % agarose gels for analysis. Primer sequences
are available from Table S1 (Oligo DNA information).
CGH analysis
Array probe design, chip hybridization, and data analysis
were performed by Roche NimbleGen (www.nimblegen.com).
FISH analysis
Human COT-1 FISH and hChr-specific multi-color FISH were
performed as previously described [12]. To specifically stain
the hIGH, hIGK and hIGL loci, probes were synthesized from
DNA derived from BAC clones RP11-417P24, RP11-316G9
and RP11-22M5 (MBL-EBI and Sanger Institute: http://
www.ensembl.org/index.html), respectively.
Somatic cell nuclear transfer
Cloned fetuses and calves were produced using chromatin
transfer procedure as described previously [19].
Flow cytometry analysis
Flow cytometry analysis on B cell development in newborn
Tc calves was performed as previously described [12], except
for some of the detection antibodies used. To detect surface
hIgG on Tc bovine B cells, goat anti-hIgG (Life Technologies,
Grand Island, NY) directly labeled with AF 488 was used. To
label surface hIgκ or hIgλ on Tc bovine B cells, mouse anti-hIgκ
antibody directly labeled with PE (Biolegend, San Diego, CA)
or mouse anti-hIgλ antibody directly labeled with PE (Southern
Biotech, Birmingham, AL) was used. To label surface bIgλ or
bIgκ on the B cells, mouse monoclonal anti-bIgλ (in-house
clone 132D7) or mouse monoclonal anti-bIgκ (in-house clone
132B10) followed by Zenon mouse IgG1PE labeling (Life
Technologies, Grand Island, NY) were used. Staining was
done by a standard protocol and then analyzed by FACSAria
flow cytometer (BD Biosciences, San Jose, CA). Briefly, 106
cells were incubated with primary antibody on ice for 20 min.
After washing twice, the cells were incubated with appropriate
secondary antibody for 20 min on ice if the primary antibody is
not directly labeled with a fluorochrome. Finally, the cells were
washed followed by re-suspend in FACS stain media for
reading.
ELISA
Total hIgG ELISA assay was performed as previously
described [12]. For fully hIgG/hIgκ or hIgG/hlgλ detection, goat
anti-hIgκ affinity-purified or goat anti-hlgλ affinity-purified
(Bethyl, Montgomery, TX) as a capture and goat anti-hIgG Fc-
HRP (Bethyl, Montgomery, TX) as a detection antibody were
used. For hIgG/bIgκ detection, mouse monoclonal anti-bIgκ (in-
house clone 132B10) as a capture and mouse anti-hIgG Fcγ-
HRP (Jackson immunoResearch, West Grove, PA) as a
detection antibody was used. For detection of hIgG1 or hIgG2,
mouse anti-hIgG1 Fc or mouse anti-hIgG2 Fc (Hybridoma
Reagent Laboratory, Baltimore, MD) as a capture and mouse
anti-hIgG HRP (Southern Biotech, Birmingham, AL) as a
detection antibody were used.
Human Antibody Levels in Transchromsomic Cattle
PLOS ONE | www.plosone.org 14 October 2013 | Volume 8 | Issue 10 | e78119
Immunization of human oral squamous cell carcinoma
to cKSL-HACΔ/DKO calves.
cKSL-HACΔ/DKO calves were immunized with X-ray-
irradiated human oral squamous cell carcinoma (DSMZ)
antigen at 2 x108 cells/dose formulated with Montanide ISA 25
adjuvant (Seppic, Puteaux, France) as water-in-oil emulsion
plus Quil A (Accurate Chemical & Scientific Corp, Westbury,
NY) as immune stimulant. The Tc calves were immunized two
times at 3-week intervals (primary immunization followed by the
booster after 3 weeks). Vaccine was administered by
intramuscular injection in the neck region. Serum samples were
collected as previously described [5] before each immunization
(V1 and V2) and 10 days and 14 days after each immunization
for antibody titer analysis. Anti-human oral squamous cell
carcinoma antibody titers were determined by flow cytometry
analysis.
Measurement of anti-human carcinoma cell hIgG/hIgκ
titer in Tc animal sera by flow cytometry
Sera collected from Tc calves immunized with human
carcinoma cells were used as the primary antibody to stain the
human carcinoma cells. Pre-immune Tc calf serum (V1, day 0)
was used as the negative controls. AF488-conjugated goat
anti-hIgG Fc (Invitrogen, Grand Island, NY) at 1:80 dilution and
PE-conjugated mouse anti-hIgκ (Biolegend, San Diego, CA) at
1:8 dilution were used to detect bound hIgG/hIgκ antibody. The
assay was performed in PBS supplemented with 4 % horse
serum, 0.1% sodium azide and 2 mM EDTA. The results were
expressed as mean fluorescence intensity (MFI) as measured
by FACSAria flow cytometer (BD Biosciences, San Jose, CA).
Supporting Information
Table S1.  Oligo DNA information.
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